ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, May 16, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
05/03/202499,955,53587,891,239



For further information on Cellectis, please contact:     

Media contact:      

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,

Investor Relations contacts:      

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

Attachment



EN
16/05/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Di...

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by ...

18h / 49m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis dévoile une approche de thérapie génique non-virale pour tra...

Cellectis dévoile une approche de thérapie génique non-virale pour traiter la drépanocytose dans Nature Communications NEW YORK, 12 juin 2024 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, annonce aujourd’hui la publication d’un article dans Nature Communications, dévoilant une approche de thérapie génique non-virale pour traiter la drépanocytose. La drépanocytose e...

18h / 49m 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights05/31/2024100,093,63588,029,374 For further information on Cellectis, please contact:      Media contact:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor R...

June 5, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 juin 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote31/05/2024100 093 63588 029 374 Pour de plus amples informations sur Cellectis, veuillez contacter :         Contact média :         Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro...

June 5, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic...

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:  CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that the European Commission (EC) has granted an Orphan Drug Designation (ODD) to its product candidate UCART22, for the treatment of Acute Lymphoblastic Leukemia (ALL). UCART22 is an allogeneic CAR T-cel...

June 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch